L-MIND Phase 2 trial

March 10, 2020March 10, 2020

Tafasitamab Plus Revlimid Granted FDA Priority Review for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration (FDA) has granted priority review to MorphoSys’ application seeking approval of its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat people with relapsed ... Read more

January 14, 2020January 14, 2020

MorphoSys Requests FDA Approval of Tafasitamab for Relapsed or Refractory DLBCL

News

MorphoSys is asking the U.S. Food and Drug Administration (FDA) to approve its CD19 antibody tafasitamab, in combination with Revlimid (lenalidomide), to treat patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

March 19, 2018March 19, 2018

MorphosSys Therapy and Revlimid Eliminate Cancer in a Third of DLBCL Patients, Phase 2 Trial Shows

News

A combination of MorphoSys‘ MOR208 and Revlimid (lenalidomide) eliminated cancer cells in almost a third of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a Phase 2 clinical trial shows. Tumor ... Read more

November 3, 2017

MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more